作者
Jonathan P Troost, Anne Waldo, Noelle E Carlozzi, Shannon Murphy, Frank Modersitzki, Howard Trachtman, Patrick H Nachman, Kimberly J Reidy, David T Selewski, Emily G Herreshoff, Tarak Srivastava, Keisha L Gibson, Vimal K Derebail, Jen Jar Lin, Sangeeta Hingorani, Alessia Fornoni, Fernando C Fervenza, Kamalanathan Sambandam, Ambarish M Athavale, Jeffrey B Kopp, Heather N Reich, Sharon G Adler, Larry A Greenbaum, Katherine M Dell, Gerald Appel, Chia-shi Wang, John Sedor, Frederick J Kaskel, Richard A Lafayette, Meredith A Atkinson, John C Lieske, Christine B Sethna, Matthias Kretzler, Michelle A Hladunewich, Kevin V Lemley, Elizabeth Brown, Kevin E Meyers, Crystal A Gadegbeku, Lawrence B Holzman, Jonathan Ashley Jefferson, Katherine R Tuttle, Pamela Singer, Marie C Hogan, Daniel C Cattran, Laura Barisoni, Debbie S Gipson
发表日期
2020/8
期刊
Clinical kidney journal
卷号
13
期号
4
页码范围
597-606
出版商
Oxford University Press
简介
Background
Understanding the relationship between clinical and patient-reported outcomes (PROs) will help support clinical care and future clinical trial design of novel therapies for focal segmental glomerulosclerosis (FSGS).
Methods
FSGS patients ≥8 years of age enrolled in the Nephrotic Syndrome Study Network completed Patient-Reported Outcomes Measurement Information System PRO measures of health-related quality of life (HRQoL) (children: global health, mobility, fatigue, pain interference, depression, anxiety, stress and peer relationships; adults: physical functioning, fatigue, pain interference, sleep impairment, mental health, depression, anxiety and social satisfaction) at baseline and during longitudinal follow-up for a maximum of 5 years. Linear mixed-effects models were used to determine which demographic, clinical and laboratory features were associated …
引用总数
20212022202320246743